Posted by Michael Wonder on 08 Mar 2021
Genentech provides update on Tecentriq U.S. indication in prior-platinum treated metastatic bladder cancer
7 March 2021 - Genentech today announced that the company is voluntarily withdrawing the U.S. indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial carcinoma.
This decision was made in consultation with the U.S. FDA as part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their outcome(s) and have yet to gain regular approvals.
Genentech will work with the FDA over the coming weeks to complete the withdrawal process.
